Theinjectionofnewprogress.docVIP

The injection of new progress 注射剂的新进展The injection of new progress随着新药开发成功，与其配套的注射液和粉针剂等制剂一起被推上市场，脂质体注射剂和长效注射剂出现了引人瞩目的发展。With the successful development of new drugs, the matched injection and tpi, etc with preparations on market, liposomes injection and long-term injection appeared remarkable achievement.1 脂质体注射液1 liposome injection2000年，世界脂质体产品销售额为12亿美元。In 2000, the world of liposome product sales of $1.2 billion.预测至2005年将达33亿美元，增长率为175%。Forecast to 2005 will reach to 3.3 billion usd, increasing 175%.美国专门从事脂质体研究与开发的公司主要有3个：明日之星制药(NexstarThe United States specializing in liposome research and development of the company mainly have three: star pharmaceutical (NexstarPharmaceuticals)、脂质体公司(The Liposome Company)和塞奎斯制药(Sequus Pharmaceuticals)。Pharmaceuticals), liposomes Company (The Liposome Company) and plug justice pharmaceutical (Sequus Pharmaceuticals).国外已上市的脂质体药物品种有两性霉素、多柔比星和柔红霉素。Overseas has listed the liposome drug varieties with too many soft sexes, than star and soft erythromycin.美国FDA已批准了奇龙(Chiron)公司/斯基制药(Skye Pharma)公司的阿糖胞苷脂质体注射液，蛛网膜下腔用药治疗非何杰金氏淋巴瘤严重并发症淋巴瘤性脑膜炎，商品名为DepoCyt。The FDA has approved the odd dragon (Chiron) company /, another pharmaceutical (Skye Pharma) company cytarabine liposome injection, subarachnoid medicine non-hodgkins lymphoma serious complications lymphoma sex meningitis, called DepoCyt goods.本品系一阿糖胞苷注射用缓释制剂，用称之为贮库泡沫(DepoFoom)的脂质基质包裹系统制成，2周1次直接注入脑脊液中，而不是常规蛛网膜下腔化疗1周2次用药。This product is a cytarabine injection sustained-release preparations, with the library called bubble (DepoFoom) lipid matrix wrapping system is made, 2 weeks injected directly into one of cerebrospinal fluid, rather than conventional subarachnoid chemotherapy 1 week 2 times drug use.此次批准标志着美国有了贮库泡沫注射技术的首???产品。The approval, marked the with the foam injection technology library first products.法玛西亚-普强(Pharmacia Upjohn)公司与新制药(Neopharm)公司达成协议，开发与上市后者2个抗癌药品紫杉酚脂质体(LEP)和多柔比星脂质体(LED)。Jordan farmar west Asia-PuJiang (Pharmacia Upjohn) company and the new drug (Neopharm) co